Vance R. Brown - 13 Feb 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Feb 2026, 17:57:46 UTC
Prior SEC filing
17 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Vance R. Brown filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 18 Feb 2026.

Key facts

  • This page summarizes Vance R. Brown's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
  • 11 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 18 Feb 2026, 17:57.

Change

  • Previous filing in this sequence was filed on 17 Feb 2026.
  • Current net transaction value: -$1,089,339.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001868243 Primary reporting owner

Brown Vance R

Relationship
EVP, GC and Corp. Secretary
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH
Signature
/s/ Susan Thompson, Attorney-in-Fact
Signature date
18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSX transaction

Common Stock

Award

Transaction value
$0
Shares
+14,804
Change %
+43%
Price
$0.000000
Shares after
49,209
Date
13 Feb 2026
Ownership
Direct
Footnotes
F1
BSX transaction

Common Stock

Award

Transaction value
$0
Shares
+14,804
Change %
+30%
Price
$0.000000
Shares after
64,013
Date
13 Feb 2026
Ownership
Direct
Footnotes
F2
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+1,118
Change %
+1.7%
Price
$0.000000
Shares after
65,131
Date
13 Feb 2026
Ownership
Direct
Footnotes
F3
BSX transaction

Common Stock

Tax liability

Transaction value
$955,946
Shares
-12,792
Change %
-20%
Price
$74.73
Shares after
52,339
Date
13 Feb 2026
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+1,851
Change %
+3.5%
Price
$0.000000
Shares after
54,190
Date
14 Feb 2026
Ownership
Direct
Footnotes
F3
BSX transaction

Common Stock

Tax liability

Transaction value
$66,883
Shares
-895
Change %
-1.7%
Price
$74.73
Shares after
53,295
Date
14 Feb 2026
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+1,839
Change %
+3.5%
Price
$0.000000
Shares after
55,134
Date
16 Feb 2026
Ownership
Direct
Footnotes
F3
BSX transaction

Common Stock

Tax liability

Transaction value
$66,510
Shares
-890
Change %
-1.6%
Price
$74.73
Shares after
54,244
Date
16 Feb 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-1,118
Change %
-25%
Price
$0.000000
Shares after
3,357
Date
13 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,118
Exercise price
Footnotes
F3, F4
BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-1,851
Change %
-50%
Price
$0.000000
Shares after
1,851
Date
14 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,851
Exercise price
Footnotes
F3, F5
BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-1,839
Change %
-100%
Price
$0.000000
Shares after
0
Date
16 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,839
Exercise price
Footnotes
F3, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

Footnote F2

On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

Footnote F3

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F4

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

Footnote F5

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

Footnote F6

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .